Cargando…

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study

The treatment of severe chronic immune thrombocytopenia (SCITP) in pediatric patients is challenging. We evaluated the clinical efficacy and safety of eltrombopag in children with SCITP in China. This observational study was carried out at the Hematology Oncology Center, Beijing Children’s Hospital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Xiaoling, Yan, Kuo, Ma, Jingyao, Chen, Zhenping, Zhao, Libo, Wang, Xiaoling, Wu, Runhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710667/ https://www.ncbi.nlm.nih.gov/pubmed/31438744 http://dx.doi.org/10.1177/2058738419872120

Ejemplares similares

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Cerebral venous thrombosis in refractory idiopathic thrombocytopenia treated with eltrombopag
por: Nambiar, Vivek, et al.
Publicado: (2016)

Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study
por: Hong, Yilei, et al.
Publicado: (2023)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag
por: Yoon, Jung-Ki, et al.
Publicado: (2019)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
por: Erçalışkan, Abdülkadir, et al.
Publicado: (2022)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency
por: Scaramucci, Laura, et al.
Publicado: (2016)

Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018)

Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial
por: Chakraborty, Sajib, et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
por: Mittelman, Moshe, et al.
Publicado: (2023)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
por: Matsumoto, Megumi, et al.
Publicado: (2022)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
por: Profit, Louise
Publicado: (2006)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia
por: Maraziti, Giorgio, et al.
Publicado: (2021)

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome
por: Xu, Liping, et al.
Publicado: (2022)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
por: Çekdemir, Demet, et al.
Publicado: (2019)

Screening for Genetic Mutations for the Early Diagnosis of Common Variable Immunodeficiency in Children With Refractory Immune Thrombocytopenia: A Retrospective Data Analysis From a Tertiary Children's Center
por: Ma, Jingyao, et al.
Publicado: (2020)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
por: Chang, Hong, et al.
Publicado: (2023)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
por: Anwer, Faiz, et al.
Publicado: (2015)

Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia
por: Saito, Makoto, et al.
Publicado: (2021)

Considerations in the Management of Hepatitis C Virus-related Thrombocytopenia with Eltrombopag
por: Danish, Fazal A., et al.
Publicado: (2010)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish, Fazal-i-Akbar, et al.
Publicado: (2013)

Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag
por: Tarantino, Michael D., et al.
Publicado: (2014)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
por: Özdemirkıran, Füsun, et al.
Publicado: (2015)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease
por: Wang, Juan, et al.
Publicado: (2021)

Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia
por: Di Paola, Alessandra, et al.
Publicado: (2020)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
por: Güven, Zeynep Tuğba, et al.
Publicado: (2022)

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

P1653: CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC
por: Cai, X., et al.
Publicado: (2022)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2023)

P1634: EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA（HBV-TP）: A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL
por: Chen, Y., et al.
Publicado: (2022)

Eltrombopag Use in Thrombocytopenia for Endoscopic Submucosal Dissection of a Gastric Carcinoid
por: Kolb, Jennifer M., et al.
Publicado: (2014)

Eltrombopag Improves Refractory Thrombocytopenia in a Patient with Systemic Lupus Erythematosus
por: Shima, Natsuki, et al.
Publicado: (2018)

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
por: Elbedewy, Tamer A, et al.
Publicado: (2019)

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
por: Zaninetti, Carlo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kq4dau7auke0rkk2hn5ovmviq0